Litigation

Celgene Corporation v. Hikma Pharmaceuticals USA, Inc.

settled

2:21-cv-10398

Filed
2021-04-28
Terminated
2022-01-13

Patents at issue (1)

Summary

Celgene sued Hikma Pharmaceuticals USA for ANDA patent infringement in D.N.J., asserting 8,648,095 among other patents. Closed 2022-01-13 after settlement.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).